Fluoropyrimidine Tailored-dose Based on Uracil Concentration in Patients Treated for Digestive Carcinomas: Evaluation of Clinical Practice

NCT04918264 · clinicaltrials.gov ↗

COMPLETED

Status

334

Enrollment

OTHER

Sponsor class

Conditions

Digestive Carcinoma

Interventions

DRUG: Fluoropyrimidine treatment (5-FU or capecitabine) and dosage
OTHER: Uracil dosage
BEHAVIORAL: Overall survival

Sponsor

Hospices Civils de Lyon